Series A
US$20.5m
Glyscend Therapeutics Announces Initiation of Phase 1 Clinical Trial on the Heels of Preclinical Data Presented at EASD 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy
Glyscend has begun a Phase 1 trial in South Australia for its oral polymer diabetes therapy and presented preclinical data; its US$20.5 million Series A was led by Santé Ventures and Brandon Capital.